Propanc Biopharma, Inc. (PPCB)
NASDAQ: PPCB · Real-Time Price · USD
0.5075
+0.0065 (1.30%)
At close: Oct 2, 2026, 4:00 PM EDT
0.5068
-0.0007 (-0.14%)
After-hours: Oct 2, 2026, 7:59 PM EDT
Propanc Biopharma Employees
As of June 30, 2026, Propanc Biopharma had 2 total employees, including 1 full-time and 1 part-time employees. The number of employees did not change compared to the previous year.
Employees
2
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
n/a
Profits / Employee
-$9,897,478
Market Cap
3.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Jun 30, 2026 | 2 | 0 | - | 2 | 0 |
| Jun 30, 2025 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2024 | 2 | 0 | - | 1 | 1 |
| Jun 30, 2023 | 2 | -1 | -33.33% | 1 | 1 |
| Jun 30, 2022 | 3 | 1 | 50.00% | 1 | 2 |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| HCW Biologics | 35 |
| Aptevo Therapeutics | 33 |
| GeoVax Labs | 19 |
| VivoSim Labs | 15 |
| BioRestorative Therapies | 14 |
| Revelation Biosciences | 9 |
| Jupiter Neurosciences | 5 |
| Cadrenal Therapeutics | 5 |
PPCB News
- 5 days ago - Propanc Biopharma FY26 EPS ($17.62) - TheFly
- 5 days ago - Propanc Biopharma Provides Corporate Update & Year-End June 30, 2025-26, Financial Results - GlobeNewsWire
- 12 days ago - Propanc Biopharma issues comparative analysis of PRP versus ERAS-0015 - TheFly
- 12 days ago - Propanc Biopharma Highlights Differentiated PRP Pancreatic Cancer Data Versus Emerging Pan-RAS Program ERAS-0015 - GlobeNewsWire
- 18 days ago - Propanc Biopharma Positions PRP's EMT-Reversal Mechanism as a Complementary Backbone to Emerging RAS Inhibitors from Revolution Medicines, Inc. and Erasca, Inc. - GlobeNewsWire
- 25 days ago - Propanc Biopharma to commence first-in-human study of PRP in February - TheFly
- 25 days ago - Propanc Biopharma to Initiate World-First Phase 1b First-in-Human Study of PRP in February 2027 - GlobeNewsWire
- 5 weeks ago - Why Is Penny Stock Propanc Biopharma (PPCB) Up 245% Today? - TipRanks